NightstaRx and The University of Alberta announce the start of the first Canadian gene therapy study to treat Choroideremia
NightstaRx Ltd ("Nightstar"), the biopharmaceutical company specialising in bringing therapies for retinal dystrophies to patients, announces that the University of Alberta, has begun enrolling and...